Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Director comp.
Evelo Biosciences, Inc. (EVLO) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights – EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023 – Completed $25.5 Million Private Placement"
03/16/2023 8-K Quarterly results
Docs: "Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business Highlights"
11/14/2022 8-K Quarterly results
Docs: "Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business Highlights - Multiple Phase 2 readouts for EDP1815 in atopic dermatitis expected in 2023&#59; data from first three cohorts expected in early 1Q 2023 and fourth cohort in 2Q 2023 -"
08/11/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
10/28/2021 8-K Quarterly results
Docs: "Evelo Biosciences Reports Third Quarter 2021 Financial Results and Business Highlights –Positive Phase 2 clinical data with EDP1815 in psoriasis&#59; moving towards registration studies–"
07/29/2021 8-K Quarterly results
Docs: "Evelo Biosciences Reports Second Quarter 2021 Financial Results and Business Highlights –EDP1815 Phase 2b data in psoriasis expected in 3Q 2021–"
10/29/2020 8-K Quarterly results
Docs: "Evelo Biosciences Reports Third Quarter 2020 Financial Results and Business Highlights"
07/30/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
11/05/2019 8-K Quarterly results
Docs: "Evelo Biosciences Announces Further Positive Interim Phase 1b Clinical Data in Psoriasis and Reports Third Quarter 2019 Financial Results",
"Evelo Biosciences Reports Further Positive EDP1815 Interim Clinical Data in Patients with Psoriasis at High Dose in Phase 1b Trial",
"Corporate Slide Presentation"
08/06/2019 8-K Quarterly results
Docs: "Evelo Biosciences Announces Positive Interim Phase 1b Clinical Data and Provides Second Quarter 2019 Financial Results -EDP1815 and EDP1066 were Well Tolerated with No Overall Difference Reported from Placebo- -Clinical Response Observed Consistent with Reductions in Cellular Histological and Blood Immune Cell Biomarkers in Psoriasis Patients at Low Dose of EDP1815- -EDP1815 Phase 2 Initiation Planned for Early 2020- -Positive EDP1066 Blood Immune Cell Biomarker Data in Psoriasis Patients at High Dose- -First in Human Data Suggest that Oral Biologics that Act on Cells in the Small Intestine Modulate Systemic Inflammation- CAMBRIDGE, Mass., August 6, 2019 - Evelo Biosciences, Inc. , a biotechnology company developing oral biologics that act on cells in the small intestine with systemic ther...",
"Second Press Release issued on August 6, 2019",
"Corporate Slide Presentation"
05/02/2019 8-K Quarterly results
Docs: "Evelo Biosciences Reports First Quarter 2019 Financial Results and Recent Business Highlights -- Novel Formulation of Monoclonal Microbials Discovered, Preclinical Potency Increased by up to 30-Fold: Plan to Introduce New Formulation into Ongoing Clinical Trials in Second Half of 2019 -- -- Initial Clinical Data for EDP1066 Expected Early in Third Quarter of 2019 -- -- On Track to Deliver 10 Clinical Readouts Across 2019 and 2020 --"
11/01/2018 8-K Quarterly results
Docs: "Evelo Biosciences Reports Third Quarter 2018 Financial Results and Recent Business Highlights -- Approval to Initiate Phase 1b Trial of EDP1815 in Psoriasis and Atopic Dermatitis: Dosing of First Patient Expected in 4Q18 -- -- Initiation of Investigator-Sponsored Phase 2a Trial of EDP1503 in Metastatic Melanoma Expected in 4Q18 --"
08/02/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : August 2, 2018 EVELO BIOSCIENCES, INC. Delaware 001-38473 46-5594527 620 Memorial Drive Cambridge, Massachusetts 02139 577-0300 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the ...",
"Evelo Biosciences Reports Second Quarter 2018 Financial Results and Recent Business Highlights"
05/31/2018 8-K Quarterly results
Docs: "Evelo Biosciences Reports First Quarter 2018 Financial Results and Recent Business Highlights"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy